Business Wire

22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis

Jaa

22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content tobacco, and hemp/cannabis research, announced today that the Company has entered into a worldwide strategic research and development agreement with KeyGene, www.keygene.com, a global leader in plant research involving high-value genetic traits and increased crop yields. This exclusive, worldwide collaboration will focus on developing hemp/cannabis plants with exceptional cannabinoid profiles for medical and therapeutic use among other applications.

Cannabinoids are naturally occurring compounds found in hemp and in cannabis that have been linked to a number of potential medical benefits. The mix, concentration, and characteristics of these cannabinoids vary widely and can be optimized through molecular breeding and other modern crop improvement technologies that have been utilized extensively in other crops, but which have been utilized rarely in hemp and cannabis varieties.

The 22nd Century-KeyGene collaboration provides 22nd Century access to a unique suite of crop innovation platforms, including genomics, molecular genetics, trait discovery and breeding technologies. Under the agreement, 22nd Century will hold exclusive worldwide rights to all hemp/cannabis plant lines, intellectual property on metabolic traits, and research results that are developed through this strategic partnership. The focus of the collaboration will include:

(i) Creating a cutting-edge genetic database which utilizes the results of genomic analyses of several hundred existing, exceptional hemp/cannabis plant lines for use in the acceleration of the Company’s development and licensing of uniquely characterized and improved hemp/cannabis plants;

(ii) Enhancing genetic variation to empower 22nd Century’s development of new and significantly improved varieties of hemp/cannabis plant lines and varieties with highly desirable cannabinoid profiles optimized for medicinal or therapeutic applications;

(iii) Creating a proprietary and industry-leading high-resolution “molecular genetic map” of the entire cannabis plant genome to facilitate rapid, cost-effective breeding of innovative varieties of hemp/cannabis plants with distinctive agronomic traits;

(iv) Analyzing the genomic sequences of multiple species of the hemp/cannabis plant and identifying shared genetic markers, allowing 22nd Century to develop improved commercial hemp/cannabis plant lines more rapidly than through conventional plant breeding approaches; and

(v) Initiating the rapid-cycle generation of hemp/cannabis plant lines with distinctive cannabinoid and terpene profiles to create elite lines.

“22nd Century’s exclusive global collaboration with KeyGene is expected to yield truly remarkable and novel medicinal cannabinoid profiles and other highly desirable agronomic traits,” explained Henry Sicignano III, President and Chief Executive Officer of 22nd Century Group. “Combined with 22nd Century’s existing hemp/cannabis technology, including our existing proprietary hemp/cannabis plant lines, the KeyGene program will bolster 22nd Century’s position as a global leader in hemp/cannabis genetics and, we expect, will lead to significant commercialization ventures and other opportunities.”

“22nd Century’s work with KeyGene will greatly enhance our Company’s ability to utilize the cannabis genome and will enable us to accelerate molecular breeding of new hemp/cannabis plant varieties,” said Dr. Juan Tamburrino, 22nd Century’s Vice President of Research and Development. “We believe our collaboration with KeyGene will generate proprietary knowledge and will contribute greatly to our intellectual property and patent portfolio.”

Work on the program will occur in multiple locations in the United States and the Netherlands.

About 22nd Century Group, Inc.

22nd Century is a plant biotechnology company focused on technology which allows it to increase or decrease the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering and plant breeding. The Company’s primary mission in tobacco is to reduce the harm caused by smoking. The Company’s primary mission in hemp/cannabis is to develop proprietary hemp strains for important new medicines and agricultural crops. Visit www.xxiicentury.com and www.botanicalgenetics.com for more information.

Cautionary Note Regarding Forward-Looking Statements: This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2018, filed on March 6, 2019, including the section entitled “Risk Factors,” and our other reports filed with the U.S. Securities and Exchange Commission which attempt to advise interested parties of the risks and factors that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected.

Contact information

22nd Century Group
James Vail, Director of Communications
716-270-1523
jvail@xxiicentury.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

KCI Files Registration Statement for Proposed Initial Public Offering18.4.2019 16:00:00 EESTTiedote

Acelity announced today that its affiliate, KCI Holdings, Inc. (“KCI”), filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”), relating to a proposed initial public offering of KCI’s common stock. Prior to the effectiveness of the registration statement, there will be a restructuring as a result of which KCI will become the holding company of the businesses currently conducted by Acelity L.P. Inc. and its subsidiaries. The number of shares to be offered and the price range for the proposed offering have not yet been determined. J.P. Morgan, Goldman Sachs & Co. LLC and BofA Merrill Lynch are acting as joint book-running managers for the proposed offering. The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus related to the offering may be obtained from: J.P. Morgan, Attention: Prospectus Department c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, via tele

Amazon and Google Announce Official YouTube Apps to Launch on Fire TV; Prime Video App Coming to Chromecast and Android TV18.4.2019 16:00:00 EESTTiedote

Today, Amazon (NASDAQ: AMZN) and Google (NASDAQ: GOOGL) announced that in the coming months, the two companies will launch the official YouTube app on Amazon Fire TV devices and Fire TV Edition smart TVs, as well as the Prime Video app for streaming to Chromecast and Chromecast built-in devices. In addition, Prime Video will be broadly available across Android TV device partners, and the YouTube TV and YouTube Kids apps will also come to Fire TV later this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005212/en/ “We are excited to work with Amazon to launch the official YouTube apps on Fire TV devices worldwide,” said Heather Rivera, Global Head of Product Partnerships at YouTube. “Bringing our flagship YouTube experience to Amazon Fire TV gives our users even more ways to watch the videos and creators they love.” “We’re excited to bring the Prime Video app to Chromecast and Android TV devices, and to give our c

Strasbourg Approves the Covered Bond Legislative Package: a Milestone for the Future of the Industry and the Capital Markets Union18.4.2019 15:06:00 EESTTiedote

Following the trilogue negotiations with the Council and the European Commission on the proposal for a Covered Bond Legislative Package, the European Parliament’s Plenary adopted today in Strasbourg the text which had been approved by the Council (Coreper) on 20 March and then by the European Parliament’s Economic and Monetary Affairs (ECON) Committee on 1 April 2019. In this context, the European Mortgage Federation - European Covered Bond Council (EMF-ECBC ) welcomes the adoption of the Covered Bond Legislative Package, which aims at completing the Capital Markets Union (CMU) in Europe. The Package provides a basis for enhanced harmonisation of the European covered bond market, in line with the objectives of the CMU, reinforcing a European common qualitative benchmark for international investors and respecting well-functioning traditional markets. It moreover paves the way for the smooth introduction of this asset class in newer and emerging covered bond markets in the Union, such as

Schlumberger Announces First-Quarter 2019 Results18.4.2019 14:00:00 EESTTiedote

Schlumberger Limited (NYSE: SLB) today reported results for the first quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Mar. 31, 2019 Dec. 31, 2018 Mar. 31, 2018 Sequential Year-on-year Revenue $7,879 $8,180 $7,829 -4% 1% Pretax operating income $908 $967 $974 -6% -7% Pretax operating margin 11.5 % 11.8 % 12.4 % -30 bps -91 bps Net income - GAAP basis $421 $538 $525 -22% -20% Net income, excluding charges & credits* $421 $498 $525 -15% -20% Diluted EPS - GAAP basis $0.30 $0.39 $0.38 -23% -21% Diluted EPS, excluding charges & credits* $0.30 $0.36 $0.38 -17% -21% North America revenue $2,738 $2,820 $2,835 -3% -3% International revenue $5,037 $5,283 $4,883 -5% 3% North America revenue, excluding Cameron $2,178 $2,265 $2,285 -4% -5% International revenue, excluding Cameron $4,469 $4,581 $4,147 -2% 8% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Fir

IDEMIA Provides NOS with eSIM Management Solutions18.4.2019 13:49:00 EESTTiedote

At the occasion of the launch of the first ever eSIM (embedded SIM) service on the Portuguese market, NOS today introduces with IDEMIA an eSIM subscription management commercial service for the consumer market, based on a physical voucher approach and future evolution towards a digital voucher. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005321/en/ (Photo: IDEMIA) As a major actor in the telecom field, IDEMIA is at the forefront of the digital revolution and is committed to bringing protected and convenient experiences to mobile operator customers. IDEMIA will be providing NOS its eSIM management solutions that will provide instant digital connectivity that allows users to connect any electronic device straight out-of-the-box and link multiple devices to the same mobile subscription. eSIM offers a streamlined user experience when it comes to managing cellular connectivity for Enterprises. According to ABI Research,

AqVida and Phyton Biotech Receive Approval from European Directorate of Quality Medicines for AqVida’s Cancer-fighting Paclitaxel Injectable Finished Dosage Formulation18.4.2019 13:00:00 EESTTiedote

Phyton Biotech, a German/North American Plant Cell Fermentation (PCF®) technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, are pleased to announce today that they have received European approval from the EDQM (European Directorate of Quality Medicines) for AqVida’s paclitaxel injectable FDF. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190418005161/en/ Phyton Biotech is the world’s leading manufacturer of paclitaxel active pharmaceutical ingredient (API), utilizing its prorprietary PCF® technology process. Under the strategic partnership with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida’s Taxol generic formulation, which is produced in AqVida’s new state-of-the-art injectable manufacturing facility located in Dassow, Germany. AqVida’s ultramodern robotic manufacturing line, designed for filling cytotoxic injectables, will be utilized to pro

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme